Retrophin Inc (RTRX) - Financial and Strategic SWOT Analysis Review

Retrophin Inc (RTRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Retrophin Inc (Retrophin) is a biopharmaceutical company that discovers, develops, acquires and markets drugs for the treatment of rare diseases. The company’s products include thiola, chenodal and cholbam. It develops drugs for various catastrophic diseases. Retrophin’s pipeline products include sparsentan, used for the treatment of focal segmental glomerulosclerosis; RE-024, a product candidate to treat pantothenate kinase-associated neurodegeneration and RE-034, utilized for the treatment of severe rare diseases. The company markets its products through its distribution partners. It works in partnership with academia and independent researchers to support the development of novel solutions. The company operates in New York and Massachusetts, the US. Retrophin is headquartered in San Diego, California, the US.

Retrophin Inc Key Recent Developments


Jun 18,2019: Retrophin announces cooperative research and development agreement with NCATS and the Alagille Syndrome Alliance to identify potential therapeutics for Alagille Syndrome
May 13,2019: Retrophin appoints Sandra E. Poole to board of directors
May 07,2019: Retrophin reports first quarter 2019 financial results
Feb 28,2019: Retrophin recognizes rare disease day 2019 and honors people living with rare disease and their caregivers
Feb 26,2019: Retrophin announces fourth quarter and full year 2018 financial results

Key benefits of buying this profile include:


You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
 


Section 1 - About the Company
Retrophin Inc - Key Facts
Retrophin Inc - Key Employees
Retrophin Inc - Key Employee Biographies
Retrophin Inc - Major Products and Services
Retrophin Inc - History
Retrophin Inc - Company Statement
Retrophin Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Retrophin Inc - Business Description
Product Category: Bile Acid Products
Overview
Performance
Product Category: Thiola
Overview
Performance
R&D Overview
Retrophin Inc - SWOT Analysis
SWOT Analysis - Overview
Retrophin Inc - Strengths
Retrophin Inc - Weaknesses
Retrophin Inc - Opportunities
Retrophin Inc - Threats
Retrophin Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Retrophin Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jun 18, 2019: Retrophin announces cooperative research and development agreement with NCATS and the Alagille Syndrome Alliance to identify potential therapeutics for Alagille Syndrome
May 13, 2019: Retrophin appoints Sandra E. Poole to board of directors
May 07, 2019: Retrophin reports first quarter 2019 financial results
Feb 28, 2019: Retrophin recognizes rare disease day 2019 and honors people living with rare disease and their caregivers
Feb 26, 2019: Retrophin announces fourth quarter and full year 2018 financial results
Feb 19, 2019: NephCure Kidney International Launches Revolutionary Clinical Trial Discovery Tool For Kidney Diseases
Jan 03, 2019: Retrophin appoints Eric Dube as president and chief executive officer
Nov 01, 2018: Retrophin reports third quarter 2018 financial results
Jul 30, 2018: Retrophin Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
Jul 26, 2018: Retrophin Reports Second Quarter 2018 Financial Results and Announces CEO Transition Plan
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
 


List Of Tables


Retrophin Inc, Key Facts
Retrophin Inc, Key Employees
Retrophin Inc, Key Employee Biographies
Retrophin Inc, Major Products and Services
Retrophin Inc, History
Retrophin Inc, Other Locations
Retrophin Inc, Subsidiaries
Retrophin Inc, Key Competitors
Retrophin Inc, Ratios based on current share price
Retrophin Inc, Annual Ratios
Retrophin Inc, Annual Ratios (Cont...1)
Retrophin Inc, Interim Ratios
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Retrophin Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
 


List Of Figures


Retrophin Inc, Performance Chart (2014 - 2018)
Retrophin Inc, Ratio Charts
Retrophin Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Retrophin Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
 


Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available